bpc-157 antiviral BPC 157 as Potential Treatment for COVID-19 BPC-157 vs. TB-500 | Peptides

Conclusion BPC-157 and TB-500 are often grouped together in popular peptide discussion, but the peer-reviewed literature treats them as distinct tools with non-overlapping mechanisms, different evidence bases, and different regulatory classifications

[DOI] [PMC free article] [PubMed] [Google Scholar] 47.Tkalcevic V.I., Cuzic S., Brajsa K., Mildner B., Bokulic A., Situm K., Perovic D., Glojnaric I., Parnham M.J

Although career scientists at the agency have recommended against it, many industry insiders tell WIRED they believe the FDA will approve reclassification anyway, since the committee put together to do the assessment includes peptide boosters

Aesthetic sameness became a goal

Any ideas or experiance with this